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Summary In order to examine in detail the sensitivity to chemotherapy of tumour cells at various organ sites
and at various stages of metastasis, we have used a series of cell lines, all selected from sister subpopulations
derived from a single mouse mammary tumour, which can be distinguished and quantitated from normal cells
and from each other through growth in selective medium. For the studies described here, we used two lines,
4T07 and 66FAR, which will form colonies in vitro in medium containing 60 iM 6-thioguanine or 330 sM
2,6-diaminopurine, respectively. Both cell lines have similar sensitivity to the test chemotherapeutic agent,
melphalan, in vitro. These two tumour cell lines were treated with melphalan in vivo, when growing either in
lungs as experimental metastases at various times after cell injection or as palpable tumours growing
subcutaneously. Responses to various doses of melphalan were measured by removing lungs or subcutaneous
tumours and performing colony-forming assays in selective medium. The data indicate marked shifts in
sensitivity as a function of metastatic stage. Analyses of dose-response curves show that both cell lines were
similarly sensitive to melphalan at early times (45 min) after cell injection i.v. but became less sensitive at an
intermediate time after injection (3 days). Differences between the two lines became apparent at later times
after i.v. injection (by day 8 or 9) and in subcutaneous tumours, where a marked reduction in the shoulder of
the dose response curve was seen in line 4T07, resulting in sensitivity equal to or greater than that of early
times, whereas the dose response parameters of 66FAR remained at those of the intermediate time point.
These results show that, in heterogenous tumours, individual subpopulations of tumour cells may respond
differently to chemotherapeutic agents at various disease stages. In vitro measures of tumour sensitivity do not
predict these changes in in vivo sensitivity. Model systems similar to the one described here may yield
information which will eventually be useful in maximising the efficacy of clinically relevant adjuvant
chemotherapy regimens.
For metastases to occur in a secondary organ site, a series of
sequential events must occur (Fidler, 1978). Agents which
inhibit metastasis are usually evaluated by determining their
effect on the final outcome of this metastatic sequence, either
by the overall effect on survival or by comparing the number
or size of metastatic nodules which develop in treated vs
control animals. By using a series of mouse mammary
tumour cell lines with selectable markers, we have been able
to follow the development of experimental lung and liver
metastases from cell injection through the appearance of
visible nodules (Aslakson et al., 1991a), and have described
immunological treatments which inhibit lung colonisation at
two different steps in the metastatic sequence (Aslakson et
al., 1991b). These tumour cell lines were selected from sister
subpopulations derived from a single mouse mammary
tumour. Both the parent subpopulations and several of the
lines with selectable markers have been extensively charac-
terised, and have been shown to differ in many characteris-
tics, including sensitivity to several chemotherapeutic drugs
(Heppner et al., 1978; Miller et al., 1989a; Miller et al.,
1989b; Miller et al., 1991), ability to metastasise from a
subcutaneous site (Miller et al., 1983), and ability to form
experimental metastases in lung and liver (Aslakson et al.,
1991a). We have chosen to use this model system to examine
the sensitivity to chemotherapy of these tumour cells at
various steps in the metastatic sequence and in subcutaneous
tumours. We report here a comparison of two cell lines in
response to melphalan. Interpretation of studies involving
drug exposure in vivo may be complicated by drug pharma-
cokinetics, in that it is difficult to be certain of the exact
concentrations and timing of tumour cell exposure to drug.
We have chosen to use the drug melphalan because it is very
short-lived under physiological conditions (Parsons et al.,
1981), so the time of tumour cell exposure to drug is limited.
In addition, melphalan does not require metabolic activation,
and the relationship between its in vitro and in vivo cytoxicity
has been shown to be relatively straightforward (Frei et al.,
1988).
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Material and methods
Mice
Male BALB/c mice 8 to 12 weeks old were produced in our
animal colony, which was established by caesarean derivation
of a litter of mice from BALB/cfC3H parents obtained from
the Cancer Research Laboratory, Berkeley, CA. Tumour cell
lines used in the experiments described here grow and re-
spond to chemotherapy equally well in male and female mice.
Tumour cell lines
Tumour subpopulation lines 66 and 410.4 were isolated from
a single spontaneously arising mammary tumour from a
BALB/cfC3H mouse (Miller et al., 1983; Dexter et al., 1978).
Line 66FAR is a diaminopurine (and fluoradenine) - resist-
ant variant of line 66 obtained by stepwise selection in in-
creasing concentrations of diaminopurine, followed by 5-
fluoroadenine. Line 4T07 is a thioguanine-, ouabain-resistant
variant of line 410.4 (Miller et al., 1987). Doubling times for
these cultures in vitro were approximately 15 h, 18 h, and
13 h for lines 4T07, 66FAR, and 66, respectively (n = 3).
Plating efficiencies averaged 64% (n = 8 cultures per cell line)
and were not significantly different for the three lines.
Cell culture
Cells were grown in monolayer in DME-10, DME supple-
mented with 2.5% foetal bovine serum, 7.5% calf serum,
1 mM mixed non-essential amino acids, and 2 mM L-gluta-
mine. Cultures were split and recultured twice a week, using
0.25% trypsin plus 0.05% EDTA in Hanks buffered salt
solution to remove cells from the tissue culture flasks.
Experimental metastasis
Cells from culture were suspended with trypsin/EDTA,
rinsed once, and suspended in DME-10. Cell suspensions
(usually 2.5 x 106 ml-') were injected intravenously via the
lateral tail vein at 0.2 ml/mouse.
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Subcutaneous tumours
Cells from culture were suspended as above, at 3 x 106
cells ml-'. Cells were injected s.c. on the right flank, at
0.1 ml/mouse. Tumour size was measured in two perpen-
dicular diameters with Vernier calipers twice a week.
Melphalan treatment
Melphalan (Sigma Chemical Co., St. Louis, MO) was
prepared immediately before use by suspending in acid
alcohol (1 ml of 12 N HCI in 120 ml 95% ethanol) to 40 mg
ml-,, diluting in acid saline (0.05 N HCI in 0.15 N NaCl) to
18 mgml', then diluting with 0.5% (w/v) carboxymethyl-
cellulose (Sigma Chemical Co.) in phosphate-buffered saline
to a final concentration of 1.8 mgml-' (Schmid, et al., 1980).
Melphalan solutions were prepared so as to insure a mini-
mum time lapse between dissolving the melphalan powder
and injecting the mice, because the solutions are unstable.
We performed a bioassay to determine the stability of these
injectable solutions by treating monolayer cultures with mel-
phalan solution stored at room temperature for various
times; loss of activity was not significant for up to 1 h
storage, but subsequently, the loss of activity accelerated
rapidly. Consequently, we always were careful to prepare and
use melphalan solutions as soon as possible (always within
1 h) after dissolving the melphalan powder. Mice were
weighed and injected with up to 18 mgkg-' melphalan i.p.
(0.01 ml per g body weight). This dose was non-lethal for up
to 48 h. Only five mice receiving this dose were retained for
longer times; one in five died at day 18 after treatment but
the cause of death may have been metastatic disease rather
than drug toxicity. Untreated control mice received 0.3 ml
vehicle (acid alcohol, acid saline, carboxymethylcellulose in
phosphate-buffered saline mixture without melphalan). The
melphalan solution of 1.8 mgml-' was diluted with vehicle in
order to inject lower doses for dose-response curves.
Recovery ofcolony-forming cells
At various times after injection of cultured tumour cells,
groups of mice were killed by cervical dislocation. Lungs
were removed aseptically, weighed, placed in Hanks buffer,
and minced finely. Lungs were dispersed by a combination of
physical and enzymatic techniques, as previously described
(Miller et al., 1990). Briefly, minced lungs were presoaked for
1 h at 0°C in 5 ml of enzyme solution consisting of serum-
free Waymouth's medium containing 1.5 mgml-' collagenase
type IV (Sigma Chemical Co.) and 36 units of porcine pan-
creatic elastase (ICN, Costa Mesa, CA). Medium containing
10% serum (5 ml/sample) was added before mechanical
dispersion. Our previous procedure was modified in that each
sample was dispersed with two sequential 30 s bursts fol-
lowed by two sequential 1 min bursts in a Stomacher blender
(Techmar Co., Cincinnati, OH). Following each blender
treatment, undispersed pieces were allowed to settle briefly,
then each supernatant medium containing suspended cells
was removed and replaced with DME-10. Pooled lung cell
suspensions were centrifuged to pellet cells, resuspended in
DME-10, and an aliquot was diluted with trypan blue to
determine live and dead cells. No attempt was made to
distinguish tumour cells from nucleated normal cells, but red
blood cells were not counted. Cell suspensions consisted
almost entirely of single cells.
Subcutaneous tumours were similarly removed and dis-
persed, using a different enzyme solution (Miller et al., 1990),
consisting of 10ml of DME-10 containing 2mgml1' col-
lagenase type 3 (Worthington Biochemical Corp., Freehold,
NJ) and 1 mgml1' hyaluronidase (Sigma Chemical Co.), and
similar Stomacher blender treatment. Cells from tumours
were rinsed twice, then passed four times through a 25 g
needle to achieve a single cell suspension (Miller et al., 1990).
Colony-formation assay
Cell suspensions were plated in 6-well tissue culture plates for
colony formation. For lungs, each cell suspension was plated
at 103 to 105 live (trypan blue-excluding) cells per well (three
wells per dilution), or at 106 or 3 x 106 live cells per 100 mm
tissue culture dish. For subcutaneous tumours, each cell
suspension was plated at 300 to 2.25 x 104 live cells per well,
also at three wells per dilution. Medium used was DME-10
containing 6014M thioguanine for line 4T07 cells, and DME-
10 containing 330fM 2,6-diaminopurine for line 66FAR
cells. Cell suspensions obtained from normal lungs without
tumour cells formed no colonies in either medium when
plated at comparable densities. After 9-14 days in 10% CO2
atmosphere at 37C, colonies were fixed with 2:1
methanol:acetic acid, stained with crystal violet, and counted
with the aid of a dissecting microscope. Only colonies of
>32 cells were counted. The colony-forming efficiency of
each cell suspension (the percent of live cells plated which
were able to form colonies) was calculated from the median
number of colonies per well, using wells with a countable
number of colonies (usually seven to 70 colonies per well or
dish). The colony-forming efficiency multiplied by the
number of live cells per lung or subcutaneous tumour yielded
the number of colony-forming cells per lung or tumour.
Dose-response curves
All data in terms of colony forming cells per lung or tumour
from each experiment were converted to a percentage of the
mean control (vehicle-treated) value for that experiment.
Regression analysis was used to fit the dose-response curve
for each experiment. Values for ID90 were obtained from
fitted curves. The shape of each dose response curve was also
described by the parameters Do and Dq. Do was defined as
the dose necessary to reduce colony formation by an amount
l/e in the exponential portion of the curve. Thus it is propor-
tional to the inverse slope. Dq, the quasi-threshold dose, was
obtained by extrapolating the exponential portion of the
curve upward until it crossed the horizontal line drawn
through the control (100% survival) value. Thus it describes
the width of the shoulder at low drug concentrations (Hall,
1988). Throughout the dose range of Dq, the response per
unit dose of drug is probably not zero, but it is clearly less
than the final exponential rate of loss of colony forming
ability seen at higher doses.
Results
Melphalan sensitivity in vitro
We have previously described the sensitivity of lines 4T07
and 66 to 2 h treatment with melphalan in vitro (Miller et al.,
1991), by measuring the ability of each cell line to form
colonies after treatment in monolayer culture. The shape of
each dose-response curve was signified by D., which is pro-
portional to the inverse slope in the exponential portion of
the dose response curve and by Dq, which describes the width
of the shoulder at low melphalan concentrations. In mono-
layer cultures, both cell lines had fairly similar D. values (line
4T07 averaged 3.4iLM in 19 experiments, and line 66
averaged 4.01tM in 12 experiments) and Dq values (approx-
imately 6gM). In the present study, we measured the sen-
sitivity of line 66FAR, a cell line derived from line 66, to 2 h
melphalan in three separate experiments, and repeated
measurements with line 4T07 and line 66 in parallel in all
three experiments. These data are shown in Table I. In these
experiments, one dish per cell line was treated with each of
four concentrations of melphalan (7-20jaM, plus no drug
controls) for 2 h, after which cells were rinsed, suspended,
and replated at low density (102-I0O cells per 35 mm dish)
and the median colony-forming efficiency at each concentra-
tion obtained from plates with a countable number of col-
onies was plotted vs each concentration. In all three20 B.E. MILLER et al.
Table I Sensitivity of cell lines in vitro to melphalan
Parameters of dose-response curvesa
Cell line D. (AM) Dq (AM)
4T07 2.8 0.4 (3)b 4.0 1.9
66 3.7 0.9 (3) 6.4 3.0
66FAR 2.1 0.1 (3) 2.0± 1.9
aCells in monolayer culture were treated for 2 h with various
concentrations ofmelphalan, then suspended and replated for colony
formation. bMean ± s.d. (number of experiments).
experiments, each data set fit an exponential (first order)
curve with a low dose shoulder (correlation coefficients were
- 0.98 to - 0.996 throughout the dose range used).
Therefore, we chose again to express these data by D. and
Dq to describe, respectively, the slope and low-dose shoulder
of each curve. As shown in Table I, lines 4T07 and 66 Do
values were similar to those previously described. Line
66FAR was slightly, although not significantly, more sen-
sitive in monolayer culture than either other line (comparing
Do values, P<.08 by t-test). These mean Do and Dq values
correspond to ID50 values of approximately 5.5 AiM, 8.2fLM,
and 3.4pM, respectively, for lines 4T07, 66, and 66FAR.
Growth oftumour cells in lungs after melphalan treatment in
vivo
In order to determine the melphalan sensitivity of tumour
cells in vivo, we assayed the colony-forming ability of tumour
cells in vitro after in vivo treatment. To determine an appro-
priate time after treatment for removal of tumour cells from
mouse lungs for assay, we injected 5 x 105 line 4T07 cells i.v.
into mice, and 3 days later we treated with a single bolus of
12 mgkg-' melphalan. We then measured the number of
colony-forming line 4T07 cells per lung at various times
between 1 and 96 h after treatment. Shown in Figure 1 is the
growth of line 4T07 in lungs of control and melphalan-
treated mice. The number of colony-forming cells increased
exponentially in control mice over several days, with a doubl-
ing time of 13.7 h. Melphalan treatment had the effect of
lowering the number of colony-forming cells per lung, as
shown, but the doubling time of the surviving line 4T07 cells
after treatment (13.4 h) was very similar to that in control
mice. Comparison of the two lines at each time point sug-
gests that the loss of colony-forming ability was slightly, but
not significantly, higher when lungs were removed 1 h after
treatment vs at later times. (The percent inhibition obtained
by comparing the (geometric) mean number of colony-
forming cells per lung in treated vs control animals was 91%
for lungs removed at 1 h, and 83% when all time points were
pooled.) The similar loss of colony-forming ability when
tumour cells were allowed to remain in situ several hours or
days after treatment compared to those removed soon after
treatments seems to indicate that repair of potentially lethal
damage has very little effect in this system. In subsequent
experiments, for convenience, mice were sacrificed and lungs
removed either at 24 h after treatment, or at both 24 h and
48 h after treatment.
Sensitivity to melphalan at different metastatic stages
For melphalan dose-response studies in vivo, tumour cells
(either 5 x 105/mouse or 5 x 104/mouse) were injected i.v. At
times ranging from 45 min to 15 days after cell injection, the
mice were injected i.p. with melphalan doses between 6 and
18 mgkg'. In each experiment, a group of control mice
received vehicle alone. After 24 h (and in some experiments,
again at 48 h), four mice per treated group and 4 control
mice were sacrificed, and their lungs were harvested,
suspended, and plated in selective medium for colony-
forming assays. Cell yields from lung digests averaged
2.7 x 107 total cells/lung, and 1.5 x 107 live (trypan-blue exc-
luding) cells/lung (527 mice analysed in 23 experiments).
There were no significant differences in total or live cell yield
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Figure 1 Growth in lungs of colony-forming cells of line 4T07
after melphalan treatment in vivo. Tumour cells (5 x 105/mouse)
were injected i.v. Three days later, melphalan (12mgkg-') or
vehicle was injected i.p. into 20 mice per treatment group. At
various times (1 to 96h) after treatment, lungs from four mice
per treatment group were removed, and cells were suspended and
assayed for colony-forming ability in thioguanine medium.
Points, means; bars, s.d.; solid line, regression line calculated
using data from vehicle-treated mice; dashed line, regression line
calculated using data from melphalan-treated mice.
between different treatment groups, between groups
harvested at different times after cell injection, between
groups injected with different numbers of tumour cells, nor
between groups bearing line 4T07 vs line 66FAR tumour
cells, indicating that the majority of total cells and live cells
recovered were host cells rather than tumour cells.
Differences in the number of cells able to form colonies in
selective medium did exist between these groups, as indicated
below. The number of colony-forming cells per lung was
calculated for each mouse and plotted vs the melphalan dose.
The data for one such experiment using line 4T07 are shown
in Table II.The data for 12 such experiments in which animals
bearing line 4T07 were treated with melphalan at various
times after cell injection are shown in Figure 2. In these
experiments, we waited 24 h after treatment before removing
lungs for assay. The data shown in Figure 2 are expressed as
percent of clonogenic cells found in lungs of control (vehicle
treated) mice. Only one-tenth as many tumour cells were
injected into mice to be treated at day 9 and day 15, in order
to insure that they would not have a huge tumour burden by
the time of harvest. In addition, in one experiment of the five
in which treatment was 3 days after cell injection (panel b),
we injected 5 x I04 cells per mouse (see figure legend).
Data for the 12 dose-response curves are summarised in
Table III in terms of D., Dq, and ID90. Correlation coeffic-
ients obtained for the exponential portion of each curve
described in Table II ranged from -0.6 to - 0.9 using all
data points, and -0.90 to -0.99 using mean values. There
was little evidence of leveling off at higher dose levels. As
shown in Table II, when line 4T07 cells were treated 45 min
after injection, the dose-response curves were relatively steep,
with Do values averaging 2.0 mgkg-', with medium widthMELPHALAN RESPONSE DURING METASTATIC GROWTH 21
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Figure 2 Effect of melphalan on the colony-forming ability of line 4T07 cells which were treated in vivo. a, Tumour cells (5 x 101
cells/mouse) were injected i.v., and melphalan at the doses shown was administered i.p. 45 min later. After 24 h, mice were
sacrificed, lungs removed and suspended, and colony-forming assays were performed on each suspension. Data expressed as
colony-forming cells/mouse were converted to the percent of mean controls (lungs from vehicle-treated mice) in each experiment.
Each line represents a single experiment. Points, means; bars, s.d.; n = 4 to 8. Curves were fitted by regression analysis, using data
from melphalan-treated animals (not vehicle treated animals). Lines were extrapolated upward to the 100% survival value (vehicle
treated) as shown in order to determine D0. In vehicle-treated controls, the mean number of colony-forming tumour cells/mouse
ranged from 8 x 102 to 3 x 103. b, Melphalan was administered 3 days after cell injection. In one experiment (U- --U), 5 x 104
tumour cells/mouse were injected; in the others, 5 x 105 tumour cells/mouse were injected. In controls, the mean colony-forming
tumour cells/mouse ranged from 5 x 103 to 3 x 104 for mice injected with 5 x 105 tumour cells, and was 2 x 102 for mice injected
with 5 x 104 tumour cells. c, Tumour cells were injected at 5 x 104 cells/mouse. Melphalan was administered 9 days after cell
injection. The mean number of colony-forming tumour cells/mouse in controls was 7 x 103. d, Tumour cells were injected at
5 x 104/mouse. Melphalan was administered 14 or 15 days after cell injection. The mean number of colony-forming cells/mouse in
controls ranged from 6 x 104 to 3 x I05.
shoulders (Dq values averaging 3.6 mg kg-'), yielding ID91
values averaging 7.9 mg kg-l. When treated 3 days after cell
injection, however, line 4T07 cells were less sensitive to mel-
phalan (Do values averaging 3.8 mg kg-', Dq values averag-
ing 5.8 mg kg-', ID90 values averaging 14.5 mgkg-'. Line
4T07 cells treated 9 or 15 days after injection continued to
exhibit D. values of 3 to 4 mg kg- ', but the low-dose
shoulder on the dose-response curves was sharply reduced
(Dq averaged 1.1 mg kg' on day 14/15, P<0.02 by Wil-
coxon two sample test compared to day 3), yielding an
average ID90 value of 7.4 mg kg-'.
Similar experiments to those shown in Figure 2 and Table
III were carried out with line 66FAR. These experiments are
shown in Figure 3 and Table IV.
As shown in Table IV, when line 66FAR cells were treated
immediately after injection, they responded very similarly to
line 4T07, with D. values averaging 2.9 mg kg-', Dq averag-
ing 2.6 mg kg-', and ID9, values averaging 9.1 mg kg-'.
Treatment on day 3 after cell injection affected the dose-
response similarly to line 4T07 as well, in that Dq increased
significantly (P<0.05), resulting in a significant increase in
ID90 as well (P< 0.05). However, in contrast to line 4T07,
line 66FAR cells treated later (day 8 and day 14 after injec-
tion) did not lose the low-dose shoulder in the dose-response
curve, and therefore, their ID90 remained relatively high.
Mice in one additional experiment (not shown) were treated
on day 19. In this experiment, D. = 3.1, Dq = 4.5, and
ID90 = 11.6 mg kg-', indicating that the low dose shoulder
was retained even as late as day 19 in this cell line.
As indicated in Figures 2 and 3 legends, there was a great
deal of variability (up to 6 fold) in mean values for the yield
of colony-forming cells per lung in control mice between
replicate experiments, as well as between individual mice
within any single experiment. In order to compare experi-
Table II Response of line 4T07 in lung to melphalan in one
experimenta
Dose of melphalan Colony forming
(mgkg-') cells/lung ± s.d.b
0 9.9 x 102 (8)C (3.0-32) x 102
9 5.1 x 10' (7) (2.5-10.6) x 10'
12 1.3 x 10' (8) (0.57-3.0) x 10'
15 4.4 x 100 (6) (2.7-7.4) x 100
Dose response curve parametersd: Do = 2.4 mg kg-1, Dq = 2.1 mg
kg-', ID90 = 7.3 mgkg-', correlation coefficient = -.823 (21 points)
aLine 4T07 cells were injected at 5 x I05 cells/mouse in 0.2ml
medium. After approximately 45 min, melphalan or vehicle was
administered i.p. at the dose shown. After 24 h, mice were sacrificed,
and lungs were removed, cells suspended, and cells were plated for
colony formation at 101 to 3 x 106 cells/dish in DMEIO containing
60luM thioguanine. bValues represent± one s.d. around the
geometric mean. CGeometric mean (number of mice). dCurve was
fitted by regression analysis, using the 21 data points obtained from
the three doses of melphalan.
Table III Sensitivity of line 4T07 to melphalan in mouse lung
Day of Parameters of dose-response curves'
treatment D. (mgkg-') Dq (mgkg-') ID90 (mgkg-')
0 2.0 0.5 (2)b 3.6 1.3 (2) 7.9 0.1 (2)
3 3.8± 1.4 (5) 5.8± 1.8 (5) 14.5±3.8 (5)
9 3.4 (1) 1.3 (1) 9.5 (1)
14/15 3.3+±1.0 (4) 1.1±0.8 (4)C 7.4±2.4(4)C
aThe parameters shown were obtained from each fitted
dose-response curve of Figure 2. bMean ± s.d. (number of experi-
ments). cSignificantly different than value at day 3 by Wilcoxon
2-sample test (P<0.02).
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Figure 3 Effect of melphalen on the colony-forming ability of line 66FAR cells treated in vivo. a, Tumour cells were injected i.v.,
and melphalan was administered i.p. 45 min later. After 24 or 48 h, mice were sacrificed, lungs removed and suspended, and
colony-forming assays were performed on each suspension. Because controls grew very little and dose-response curves were similar
between 24 and 48 h, data from both time points were pooled. In one experiment (0- -0), 3 x i0 tumour cells/mouse were
injected; in controls, the mean number of colony-forming tumour cells/mouse was 7 x 103 in this experiment. In the other two
experiments, 5 x 105 cells/mouse were injected, and the mean number of colony-forming tumour cells/mouse in controls ranged
from 9.4 x 103 to 9.7 x 103. b, Melphalan was administered 3 days after cell injection (5 x 105 cells/mouse). In controls, the mean
number of colony-forming tumour cells/mouse ranged from 104 to 4 x 104. C, Melphalan was administered 8 days after cell
injection (2 x 105 cells/mouse). Colony-forming tumour cells/mouse averaged 5.6 x 104 in controls. d, Melphalan was administered
14 to 15 days after cell injection. Colony-forming tumour cells/mouse in controls averaged 6.3 x 104 in one experiment (0 *,
2 x 105 cells injected), 3.1 x 105 in the second experiment (O---0, 3 x 105 cells injected), 4.7 x 105 in the third experiment (105
cells injected).
ments, we expressed all data for melphalan-treated mice as a
percentage of the mean value for control mice within each
experiment, as shown. When we compared replicate experi-
ments, no significant correlation was found between the yield
of colony-forming cells per lung in controls and any of the
three dose-response curve parameters, D, Dq, or ID90. Thus,
within the range of values obtained in replicate experiments
described here, the tumour burden did not affect the sen-
sitivity to melphalan in a systematic way.
Long-lasting effect ofin vivo treatment
In some of the experiments of Tables III and IV, several
animals were retained for later necropsy. Three experiments
with line 4T07 revealed some long-lasting effects of treatment
(Table V). All 10 control mice had grossly visible metastatic
modules at three sites: all mice had >70 nodules on the lung
surface, >70 nodules on the chest wall, and a median of 13
nodules on the liver surface. Five mice treated with
15 mg kg-' melphalan on day 3 after cell injection had fewer
nodules at two sites: all mice had >70 nodules on the lung,
but a median of 1 nodule on the chest wall, and 0 on the
liver. This may be compared to the response obtained 24 h
after treatment: the number of colony-forming cells after
15 mg kg-' treatment as a percent of control was 29%. Eight
mice from two experiments treated with 15 mg kg-' mel-
phalan on day 0 had even fewer nodules than mice treated on
day 3 as expected, given the greater sensitivity indicated by
the dose-response curves constructed from the day 0-
treatment response 24 h after treatment (number of colony-
forming cells per lung 24 h after 15 mg kg-' treatment as a
percent of control was 0.2% and 0.5% in the two
experiments).
Treatment of line 66FAR in vivo 3 days after cell injection
had an effect similar to that on line 4T07 on gross metastases
found at necropsy, as well as similar effects at 24/48 h after
treatment. Ten control mice (two pooled experiments) had 38
metastatic nodules on the lung surface and eight on the chest
wall. Line 66FAR did not form grossly visible nodules on the
liver. Nine mice treated with 15 or 18 mgkg-' melphalan
had similar numbers ofnodules on the lung, but fewer on the
chest wall. This may be compared to the response 24/48 h
after treatment: 2% by 15 mgkg-' melphalan, and 13% by
18 mg kg-' melphalan. Unfortunately, no necropsies were
performed on mice treated immediately after injection (day 0)
of line 66FAR.
Sensitivity to melphalan in subcutaneous tumours
We have also determined the melphalan sensitivy of these
two tumour lines growing as subcutaneous tumours. Data
describing these dose-response curves are shown in Table VI.
Tumours were treated at a size of 0.2 to 2.3 g and harvested
24 h later. In order to construct the dose-response curves, we
expressed data from colony-forming assays as colony-form-
ing cells per gram wet weight of tumour. This allowed us to
normalise data obtained by harvesting tumours at different
times after cell injection and over a wide size range. (Separate
analyses indicate that dose response parameters did not vary
Table IV Sensitivity of line 66FAR to melphalan in mouse lung
Day of Parameters of dose-response curves
treatment Do (mgkg-') Dq (mgkg-') ID90 (mgkg-')
0 2.9 0.8 (3)b 2.6 1.4 (3) 9.1 ± 3.0 (3)
3 3.2 1.0 (4) 8.0 1.9 (4) 15.6 ± 3.6 (4)
8 2.3 (1) 9.7 (1) 15.2 (1)
14/15 2.9 ± 0.6 (3) 6.5 ± 2.3 (3)C 12.8 ± 2.0 (3)C
aThe parameters shown were obtained from each fitted
dose-response curve of Figure 3. bMean ± s.d. (number of experi-
ments). cNot significantly different than day 0 by Wilcoxon 2-sample
test.
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Table V Metastatic lesions grossly visible at necropsy
Number of metastases
Time of necropsy Lung Chest Liver
Cell line Treatment group Number mice (days after injection) surface wall surface
4T07 Control (vehicle) loa 13-21 >70 (all)b >70 (all) 13 (0-26)
15mg kg-', day 3 5c 14 >70 (all) 1 (0-11) 0 (0-1)
15mgkg-', day o 8 13-21 10 (0-38) 0 (0-1) 0 (0-2)
66FAR Control 1OC 18-28 38 (17-52) 8 (0-20) 0 (all)
15 or 18mgkg-', day 3 9f 18-28 29 (6-45) 0 (0-25) 0 (0-1)
aThree pooled experiments. bMedian number (range). cOne experiment, shown in Figure 2b, solid line. dTwo pooled
experiments, shown in Figure 2. 'Two pooled experiments. 'Two pooled experiments, shown in Figure 3b, solid and dotted
lines.
Table VI Response of tumour cell lines in s.c. tumors to
melphalan
Parameters of dose-response curves'
Cell line D. (mgkg-') Dq (mgkg-') IDE, (mgkg-')
4TO7 2.8 ± 1.1 (3)b 0.3 ± 0.5 (3) 6.6 ± 2.4 (3)
66FAR/66C 3.4±0.8 (3) 4.0± 2.0 (3)d 12.0± 3.7 (3)d
aTumour cells were injected s.c. at 3 x 101 cells/mouse. Mice were
injected i.p. with various doses of melphalan (6 to 15 mgkg-') or
vehicle when tumours averaged 0.8 g. Five to ten mice per treatment
group were sacrificed, and tumours were removed, suspended, and
plated for assay of colony-forming ability 24 h after treatment.
bMean ± s.d. (number of experiments). 'Two experiments were
carried out with line 66FAR and one with line 66; the results were
very similar. dSignificantly larger than values obtained in line 4T07
by Wilcoxon two-sample test, P<0.05.
with tumour size over the size range used.) In each experi-
ment, from five to ten tumours were treated with each dose
of melphalan and with vehicle. Melphalan doses used were 6,
9, 12 and 15 mg kg-'. Correlation coefficients ranged from
- 0.62 to - 0.98.
As shown, in three experiments with line 4T07 the low-
dose shoulder in the dose-response curve was very small. This
small low dose shoulder is similar to the response seen in late
treatment of line 4T07 cells in the lung, but different from
that seen in 4T07 cells treated at earlier time points. D.
values averaged around 3 mgkg-', again like those obtained
for late treatment in lung.
In Table VI, we have pooled one experiment done with
line 66, the parent line of line 66FAR with two 66FAR
experiments. Line 66 cannot be used in colony-forming
assays using lung tissue because it does not have a selectable
marker that allows it to be distinguished unambiguously
from colonies formed from normal lung cells. However, very
few normal cells isolated from subcutaneous tumours can
form colonies under our assay conditions (B.E. Miller et al.,
1987), so this tumour cell line can be used in colony-forming
assays from subcutaneous tumours. Treatment of line 66/
66FAR in subcutaneous tumours yielded similar D. values to
values obtained at day 3-14 in lungs. The Dq values for
these experiments were also similar to those obtained at day
3-14 in lungs, and were thus significantly greater than Dg
values obtained for line 4T07 in subcutaneous tumours
(P<0.05). ID90 values for line 66/66FAR were also
significantly greater than those obtained for line 4T07
(P<0.05).
Thus, unlike the situation in early stages of metastasis,
there appears to be a difference in sensitivity between line
4T07 and line 66/66FAR in late stage metastases and in
subcutaneous tumours. This differences is confirmed by our
previously published data indicating that subcutaneous
tumours ofline 66 are less sensitive to a single moderate dose
ofmelphalan than are line 4T07 tumours (Miller et al., 1991).
Discussion
We describe here a technique for measuring the drug sen-
sitivity of tumour cells are various stages in the metastastic
process, through the use ofcolony-forming assays to measure
the proliferative capacity of tumour cells at various times
after treatment. Such techniques are standard for measuring
chemocytotoxicity in solid tumours; however, by use of
tumour cells carrying drug-resistance markers and thus able
to grow in selective medium, thereby preventing growth of
the large excess of normal cells, we have been able to apply
this technique to cells in occult metastases as well.
Data on the changes in sensitivity of tumour cells in lungs
as a function of time after injection need to be seen in
relation to the metastatic sequence. In order for tumour cells
injected intravenously to form lung colonies, the cells must
be arrested and retained in the lung, extravasate, and rep-
licate in lung parenchyma. Previous studies with line 4T07
using similar colony-forming assays have shown that it
arrests and grows in lung in a characteristic time-dependent
manner which can be related to these several steps of metas-
tasis (Aslakson et al., 1991a, 1991b). The majority (>80%)
of line 4T07 cells injected i.v. lodge very quickly in the lungs
(Aslakson et al., 1991b), but most of these cells are killed
rapidly, so the number of tumour cells drops exponentially
for approximately 8 h, with a half time for clearance of 2 to
4 h (Aslakson et al., 1991a, 1991b). After 8 h the rate of
tumour cell loss slows. As suggested by Liotta and DeLisi
(1977), this second phase correlates with the extravasation of
line 4T07 cells from blood vessels into lung parenchyma
(Aslakson et al., 1991b). Since melphalan is a drug with a
short half-life under physiological conditions (Parsons et al.,
1981), the contact of tumour cells with active drug must be
of short duration and relatively soon after drug injection. At
the time of earliest treatment, 45 min after injection, the
tumour cells were nearly all arrested in the lung, but not
extravasated. By the time of harvest 24h after treatment,
however, the surviving cells may have completed the extra-
vasation process.
Sometime within 24 h after injection of line 4T07 cells, the
number of colony-forming tumour cells starts to rise as cell
replication begins to exceed cell death (Aslakson et al.,
1991b). The number of colony-forming line 4T07 cells in-
creases exponentially between day 1 and at least day 7 after
injection: previously measured doubling times in this growth
period averaged 21 h (Aslakson et al., 1991a, 1991b). Thus,
when mice were treated with melphalan 3 days after cell
injection, the cells were in a period of rapid exponential
growth in the lungs.
Grossly visible nodules appear on the surface of lungs of
untreated mice approximately 10 to 14 days after i.v. injec-
tion of line 4T07. When lungs of mice in experiments
depicted in Figure 2, panel d were examined prior to diges-
tion, most lungs contained visible metastases. Although we
have not measured the growth rate of colony-forming line
4T07 cells in mice with large tumour burdens in the lung,
tumour cell growth rate is likely to slow as tumour nodules
become larger. Thus, when mice were treated with melphalan
9 to 15 days after line 4T07 injection, the tumour cells were
at this late stage of metastasis.
We have not analysed the time course of growth of un-
treated line 66FAR cells in the lung. However, studies similar
to that described above for line 4T07 have been completed
for the closely related line 66c14 (Aslakson et al., 1991a).24 B.E. MILLER et al.
These studies show a pattern similar to that of line 4T07.
Both line 66c14 and 66FAR grow more slowly in the lung
that does line 4T07. The doubling time ofline 66c14 averages
39h (Aslakson et al., 1991b), whereas line 66FAR grows
even more slowly (doubling time of 54 h, not shown). Never-
theless, visible metastatic nodules are found in the lung by
day 13 to 20. Thus, when line 66FAR cells were treated with
melphalan 3 or 8 days after cell injection, they were in a
period of slow expansion of colony-forming cell number in
the lungs. By day 14-19, metastatic deposits were large
enough to be visible in many mice.
In solid tumours, it is a common observation that a treat-
ment known to cause a relatively large tumour cell kill as
determined by colony-forming assay may result in a relatively
small effect on tumour growth or host survival time (Steel,
1977). This may be due to a number offactors such as repair
of potentially lethal damage in situ, rapid regrowth of
tumour cells after treatment, and slow clearance of dead or
damaged tumour cells in vivo. We have previously shown that
melphalan treatment of subcutaneous tumours of line 4T07
results in an initial loss of colony-forming cells assayed 24 h
after treatment, followed by a gradual increase in colony-
forming cells per g tumour in treated mice so as to be in-
distinguishable from controls by day 14 after treatment
(Miller et al., 1991). We describe here that in lung metas-
tases, the difference between the number of colony-forming
tumour cells per lung in treated and untreated animals
assayed within 1 h after treatment is only slightly more than
differences seen on several days after melphalan treatment.
This suggests that repair of potentially lethal damage in situ,
which is likely to take place in the first days after treatment,
is of small consequence in this system. However, the percent
reduction in the number of metastatic nodules found at the
time of necropsy was considerably smaller than the amount
of tumour cell kill measured 24-48 h after treatment,
indicating the somewhat transient effect of treatment.
Although we saw no sign of accelerated regrowth of line
4T07 early after treatment (Figure 1), it is likely that the
tumour-burden in treated mice tends to 'catch up' to that in
untreated mice as growth slows late in metastasis develop-
ment. Increased survival time or cure in the ultimately
desired effect of treatment, but it is important to determine
immediate effects of treatment, even if they are transient,
since such information may suggest the type and timing of
subsequent effective treatment.
We have shown that tumour cell sensitivity to melphalan
varies between cells at different stages in the metastatic pro-
cess and between cell at early stages of metastasis vs cells in
palpable subcutaneous tumours. In our experiments, cells
treated relatively late in the metastatic process, after nodules
had formed, responded very like cells in subcutaneous
tumours. Such information obtained for a number of
therapeutic agents may lead to combined therapy regimens
tailored for specific disease stages.
Some tumour cell lines appear to vary more than others in
different stages of metastasis, so that two cell lines may be
similar in sensitivity at one stage and differ at another. We
have shown that line 66FAR and line 4T07 are very similar
in sensitivity to melphalan when cells are treated very soon
after i.v. injection and in early stages of growth in lungs, as
well as being similarly sensitive in vitro. However, in late
stages of growth in lungs and in subcutaneous tumours, line
4T07 is more sensitive to melphalan than is line 66FAR,
becaue it has a more consistant loss of the low-dose shoulder
of the dose-response curve. Indeed, line 4T07 cells in late
metastases were actually more sensitive to low doses of drug
than were 4T07 cells treated earlier, a result which, although
counter-intuitive, is highly reproducible.
As we indicated previously, within the range obtained from
replicate experiments, the size of the tumour burden did not
systematically affect the dose-response curve parameters des-
cribing melphalan sensitivity in either cell line. On the other
hand, there were large differences in mean tumour burden
between experiments in which mice were treated and
sacrificed early (day 0-1), at intermediate times (day 3-4) or
late (day 14-15). These differences were particularly pro-
nounced in line 4T07, which grew very rapidly in lungs, even
though we injected 10 times as many cells into mice to be
sacrificed early vs those to be sacrificed late, in order to
partly compensate for these differences. The smallest mean
tumour burden of 9.9 x 102 colony-forming tumour cells per
lung was determined in an experiment in which 5 x 10 line
4T07 cells were injected, then harvested 1 day later. The
largest mean tumour burden of 2.8 x 105 colony-forming
tumour cells per lung was found in an experiment in which
5 x 104 line 4T07 cells were injected, then harvested 15 days
later. These experiments thus represent a range of tumour
burdens of almost 300 fold. However, it does not appear that
differences in tumour burden alone can account for the
changes in sensitivity to melphalan we have described. Line
4T07 tumour cells harvested in an intermediate time (day 4),
from mice having intermediate tumour burdens (averaging
1.6 x 105 colony-forming cells per lung) were less sensitive to
melphalan (larger Do) then those treated early, and also less
sensitive (larger Dq) than those treated late. Mice bearing line
66FAR had a similar, although somewhat smaller range of
tumour burdens (smallest: 7.4 x 103 colony-forming cells per
lung from 5 x 105 injected, harvested day 1; largest: 4.7 x 105
from 1 x 105 injected, harvested day 15). However, even
though the tumour burden had become as large at 15 days in
line 66FAR as in line 4T07-bearing animals, there was not a
similar increase in melphalan sensitivity in those tumour
cells.
Further studies will be needed to determine the reasons for
these changes in sensitivity at various stages. It is well known
that chemotherapeautic agents which are cell-cycle dependent
or strongly proliferation dependent are less effective in large
tumours when many cells are out of cycle (Steel, 1977).
Melphalan is usually described as cell cycle independent;
however, it has been shown to be somewhat more cytotoxic
to cells in the M/Gl phase in at least one system (Bhuyan et
al., 1972). It is more cytotoxic for proliferating cells (Blos-
manis et al., 1987). It may be that cell cycle or cell prolifera-
tion differences between cells at various stages of metastasis
are responsible for some of the differences in sensitivity to
melphalan described here. However, the increased sensitivity
to melphalan shown by line 4T07 in late stage metastasis and
in palpable tumours is unlikely due to increasedcell prolifera-
tion at these stages; in fact, relatively few line 4T07 cells are
in cycle in subcutaneous tumours at any given moment
(Miller et al., 1987).
Some chemotherapeutic agents may be more or less
effective in larger tumours because hypoxic conditions, in-
creased cell contact, or other environmental effects may lead
to mechanistically relevant changes in cellular metabolism.
Changes in cellular metabolism which may occur at different
stage of metastasis could affect sensitivity to melphalan.
Alternatively, cells at different metastatic stages may differ in
sensitivity to melphalan because of differences in exposure to
drug, or differences in ability to repair potentially lethal
damage. It is possible that the increased sensitivity of both
cell lines to melphalan when treated 45 min after cell injec-
tion may be due to increased drug exposure before cells have
extravasated into lung parenchyma.
Studies with radiation have indicated that the extent of
sublethal damage repair often correlates with the breadth of
the shoulder in the acute dose-response curve (Hall, 1988). In
the case of melphalan cytotoxicity, Parsons reported that
time-dependent repair of certain DNA-cross-links was cor-
related with resistance to melphalan cytotoxicity at low doses
or short exposure times in one of two human melanoma lines
(Parsons, 1984). The fact that moderate to large shoulders
were seen in dose response curves to melphalan from both of
our cell lines at earlier stages of metastasis may suggest that
both lines have the ability to repair sublethal damage under
these growth conditions. However, with many chemothera-
peutic agents, there is little correlation between the extent of
the shoulder of a single dose-response curve and the
appearance of sublethal damage repair determined by in-
creased survival in split dose experiments (Hall, 1988), sug-MELPHALAN RESPONSE DURING METASTATIC GROWTH 25
gesting that low dose shoulders reflect other metabolic effects
affecting the threshold ofdrug toxicity such as reduced trans-
port of drug at low concentrations. In the experiments de-
scribed here, no shoulders or only small shoulders were seen
in dose-response curves from four of four late-stage metas-
tasis experiments with line 4T07, and from two of two sub-
cutaneous tumour experiments with line 4T07, but from none
of three subcutaneous tumour experiments and three late-
stage metastasis experiments with line 66FAR/66. It may be
that slow-developing local microenvironmental effects or host
reactions to tumour specific to line 4T07 may be instrumental
in the loss of these low dose shoulders. Such loss has so far
not been seen in a number of in vitro culture configurations,
suggesting that factors unique to the in vivo environment may
be involved. Two candidate microenvironmental factors are
extent of vascularisation and extent of inflammatory cell
infiltration, both of which vary between line 4T07 and line
66FAR/66 tumours. Experiments are in progress to test
whether either of these factors contributes to the heightened
melphalan sensitivity.
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